(RTTNews) - Bio-Path Holdings (BPTH) reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. BP1001-A downregulates growth factor receptor-bound protein 2 expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients.
Bio-Path has initiated animal studies to confirm the efficacy of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. If successful, the company plans initiating a first-in-human Phase 1 clinical trial in 2025.
Shares of Bio-Path are up 65% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
